Article By:
Terry Chrisomalis
Thursday, September 5, 2019 8:46 AM EDT
Bellicum is a highly undervalued biotech. Especially, when you consider that it has two types of technology that can be utilized to potentially alter how CAR-T therapies are produced.
In this article: BLCM
Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
How likely is finidng a partner for $BLCM?
Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
Based on history, any catalyst will lead to new lows. $BLCM